OCULAR THERAPEUTIX, INC

OCUL

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 29, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
OTX-TKI	Phase 3	Neovascular Age-related Macular Degeneration	-
OTX-TKI (axitinib implant)	Phase 3	Neovascular Age-Related Macular Degeneration	-
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24	Phase 3	Non-Proliferative Diabetic Retinopathy	-
Ophthalmic Insert	Phase 3	Open Angle Glaucoma and Ocular Hypertension	-
Dextenza Ophthalmic Insert	Phase 3	Cataract	-
Travoprost	Phase 3	Open Angle Glaucoma	-
Dexamethasone, 0.4mg	Phase 3	Allergic Conjunctivitis	-
Dexamethasone	Phase 3	Post-Surgical Ocular Pain	-
Punctum Plug	Phase 3	Post Ocular Surgical Inflammation and Pain	-
OTX-TP	Phase 2	Glaucoma	-
OTX-TIC low dose Travoprost Intracameral Implant	Phase 2	Open Angle Glaucoma	-
OTX-CSI	Phase 2	Dry Eye Disease	-
OTX-DED	Phase 2	Dry Eye	-
OTX-DP (Dexamethasone punctum plug)	Phase 2	Ocular Inflammation and Pain	-
Controlled Insertion	Phase 2	Dry Eye Syndromes	-

Catalyst Timeline

1 upcoming, 0 past

⭐Phase 3Next

Apr 29, 2026OTX-TKI (axitinib implant)

Primary completion for OTX-TKI (axitinib implant) trial (NCT06223958) in Neovascular Age-Related Macular Degeneration

Regulatory Approvals

OCUL News